$XTALPI(02228.HK) Currently, leveraging the technological advantages of the PepiX™ platform, Jingtai Technology has strategically deployed multiple self-developed and collaborative projects in the field of peptide drugs. These cover cutting-edge areas such as the development of cyclic peptides for crossing the blood-brain barrier (BBB) delivery, RDC cyclic peptide carrier development, cyclic peptide development for difficult-to-drug IDP targets, and oral peptides. In the field of RDC cyclic peptide carrier development, it has established a deep collaboration with Hangzhou Jingjiahang to develop a new generation of peptide radionuclide drugs using the innovative "AI + radiopharmaceuticals" model. In the field of metabolic diseases, it has formed a strategic partnership with Gan & Lee Pharmaceuticals, focusing on unmet core therapeutic needs in metabolic diseases by leveraging the PepiX™ platform, accelerating the discovery and development of novel peptide-based innovative drugs in areas like GLP-1, and achieving full-chain collaboration from technology R&D to clinical translation. It has also initiated an AI-driven oral peptide drug development collaboration with Hong Kong Xingweida, integrating the technological strengths of both parties to build a new generation of joint solutions and development platforms for oral peptide drugs.